JOHNSON & JOHNSON (JNJ)
US4781601046 - Common Stock
JOHNSON & JOHNSON
NYSE:JNJ (11/21/2024, 8:04:00 PM)
After market: 155.7 +0.2 (+0.13%)155.5
+2.39 (+1.56%)
Company Profile
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. The company is headquartered in New Brunswick, New Jersey and currently employs 131,900 full-time employees. The firm's primary focus is products related to human health and well-being. The company operates through two segments: Innovative Medicine and MedTech. The Innovative Medicine segment is focused on various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. Products in this segment are distributed directly to retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment includes a broad portfolio of products used in the orthopedic, surgery, interventional solutions, cardiovascular intervention, and vision fields. The MedTech segment also offers a commercially available intravascular lithotripsy (IVL) platform for coronary artery disease (CAD) and peripheral artery disease (PAD).
Company Info
JOHNSON & JOHNSON
One Johnson & Johnson Plaza
New Brunswick NEW JERSEY 08933
P: 17325242455
CEO: A. Gorsky
Employees: 131900
Website: https://www.jnj.com/
JNJ News
2 days ago - BloombergJ&J, Merck Cut Jobs in China as Local Competition Takes TollJohnson & Johnson and Merck & Co. are cutting jobs in China, as they face growing competition from domestic rivals resulting from Beijing’s campaign to drive down medical costs.
3 days ago - Johnson & JohnsonJohnson & Johnson to showcase strength of its broad hematology portfolio and pipeline at the 2024 American Society of Hematology Annual Meeting/PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) announced today more than 90 abstracts featuring data from the Company's differentiated blood cancer portfolio and...
3 days ago - Zacks Investment ResearchJohnson & Johnson (JNJ) is Attracting Investor Attention: Here is What You Should KnowRecently, Zacks.com users have been paying close attention to Johnson & Johnson (JNJ). This makes it worthwhile to examine what the stock has in store.
4 days ago - Johnson & JohnsonIcotrokinra delivered an industry-leading combination of significant skin clearance with demonstrated tolerability in a once daily pill in Phase 3 topline results/PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced positive topline results from ICONIC-LEADa, a pivotal Phase 3 investigational study of...
8 days ago - Market News VideoNoteworthy Thursday Option Activity: JNJ, APAM, CAPR8 days ago - Zacks Investment ResearchWhy Is Johnson & Johnson (JNJ) Down 6.7% Since Last Earnings Report?Johnson & Johnson (JNJ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
JNJ Twits
Here you can normally see the latest stock twits on JNJ, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits:
